TRVI
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 19.66 · operating margin 0.0%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
VENTE TOTALE: 21 052 titres (~317 674,68 $ US)
- Insiders
- Heffernan Michael Thomas
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$317,675
Avg sell (VWAP, 90d window) $15.88 vs last close —
- Last activity
- 2026-09-15
- Last synced
-
2026-09-21 10:15:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-15 | Heffernan Michael Thomas | Sell | 100 | $15.88 | $1,588 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-17
TRVI is a pre-revenue biotech with zero operational income, persistent net losses, and negative cash flows, making its financial foundation extremely fragile despite adequate liquidity from financing activities.
The first sentence of the analysis written for TRVI on 2026-09-17 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 19.659 | 10.413 | 15.032 | 9.150 | 2.983 | |
| Quick Ratio | 19.659 | 10.413 | 15.032 | 9.150 | 2.983 | |
| Solvency Ratio | -4.180 | -4.243 | -4.221 | -1.871 | -1.584 | |
| Cash Ratio | 1.940 | 3.245 | 5.563 | 0.939 | 2.895 | |
| Price To Earnings Ratio | -43.172 | -8.766 | -4.621 | -4.289 | -0.525 | |
| Price To Earnings Growth Ratio | 1.127 | -0.141 | 0.130 | 0.061 | 0.030 | |
| Forward Price To Earnings Growth Ratio | 1.127 | -0.141 | 0.130 | 0.061 | 0.030 | |
| Price To Earnings Diluted Ratio | -43.172 | -8.766 | -4.621 | -4.289 | -0.525 | |
| Price To Earnings Diluted Growth Ratio | 1.127 | -0.141 | 0.130 | 0.061 | 0.030 | |
| Price To Book Ratio | 9.914 | 4.178 | 1.608 | 1.159 | 1.046 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -43.151 | -10.872 | -4.167 | -4.396 | -0.617 | |
| Price To Operating Cash Flow Ratio | -43.164 | -10.882 | -4.185 | -4.421 | -0.617 | |
| Debt To Assets Ratio | 0.004 | 0.009 | 0.015 | 0.075 | 0.380 | |
| Debt To Equity Ratio | 0.004 | 0.010 | 0.016 | 0.085 | 0.857 | |
| Debt To Capital Ratio | 0.004 | 0.010 | 0.016 | 0.079 | 0.461 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.020 | 0.336 | |
| Financial Leverage Ratio | 1.056 | 1.113 | 1.083 | 1.145 | 2.253 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.317 | -3.640 | -5.445 | -2.103 | -2.275 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.001 | 1.004 | 1.006 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | -11,940.000 | -73.020 | -3.592 | -4.646 | |
| Interest Coverage Ratio | 0.000 | -12,881.000 | -86.760 | -38.342 | -27.018 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -4.025 | -4.962 | |
| Operating Cash Flow Coverage Ratio | -55.895 | -37.070 | -23.700 | -3.070 | -1.979 | |
| Capital Expenditure Coverage Ratio | -3,507.417 | -1,093.029 | -231.460 | -177.201 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -3,507.417 | -1,093.029 | -231.460 | -177.201 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -42.141 | -8.019 | -3.556 | -4.330 | 0.133 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 19.659 | ▲9.246 | ▲8.211 |
| Quick Ratio | 19.659 | ▲9.246 | ▲8.211 |
| Solvency Ratio | -4.180 | ▲0.063 | ▼-0.960 |
| Cash Ratio | 1.940 | ▼-1.304 | ▼-0.976 |
| Price To Earnings Ratio | -43.172 | ▼-34.407 | ▼-30.898 |
| Price To Earnings Growth Ratio | 1.127 | ▲1.268 | ▲0.886 |
| Forward Price To Earnings Growth Ratio | 1.127 | ▲1.268 | ▲0.886 |
| Price To Earnings Diluted Ratio | -43.172 | ▼-34.407 | ▼-30.898 |
| Price To Earnings Diluted Growth Ratio | 1.127 | ▲1.268 | ▲0.886 |
| Price To Book Ratio | 9.914 | ▲5.736 | ▲6.333 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -43.151 | ▼-32.280 | ▼-30.511 |
| Price To Operating Cash Flow Ratio | -43.164 | ▼-32.282 | ▼-30.510 |
| Debt To Assets Ratio | 0.004 | ▼-0.005 | ▼-0.093 |
| Debt To Equity Ratio | 0.004 | ▼-0.006 | ▼-0.191 |
| Debt To Capital Ratio | 0.004 | ▼-0.006 | ▼-0.110 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.071 |
| Financial Leverage Ratio | 1.056 | ▼-0.057 | ▼-0.274 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.317 | ▼-0.677 | ▼-0.761 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.001 | ▼-0.002 |
| Debt Service Coverage Ratio | 0.000 | ▲11940.000 | ▲2404.252 |
| Interest Coverage Ratio | 0.000 | ▲12881.000 | ▲2606.624 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲1.798 |
| Operating Cash Flow Coverage Ratio | -55.895 | ▼-18.825 | ▼-31.552 |
| Capital Expenditure Coverage Ratio | -3507.417 | ▼-2414.388 | ▼-2505.595 |
| Dividend Paid And Capex Coverage Ratio | -3507.417 | ▼-2414.388 | ▼-2505.595 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -42.141 | ▼-34.123 | ▼-30.559 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.82B | $416.3M | $132.7M | $124.6M | $17.9M | |
| Enterprise value | $1.80B | $383.2M | $101.6M | $121.2M | -$4.3M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -42.73x | -10.02x | -3.21x | -4.30x | 0.15x | |
| EV / Free cash flow | -42.72x | -10.01x | -3.19x | -4.28x | 0.15x | |
| EV / EBITDA | -42.14x | -8.02x | -3.56x | -4.33x | 0.13x | |
| Net debt / EBITDA | 0.43x | 0.69x | 1.09x | 0.12x | 0.68x | |
| Current ratio | 19.66x | 10.41x | 15.03x | 9.15x | 2.98x | |
| Income quality | 0.98x | 0.80x | 1.09x | 0.97x | 0.85x | |
| Graham net-net | $1 | $1 | $1 | $2 | $1 | |
| Tax burden | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% | |
| Interest burden | 100.0% | 100.0% | 101.4% | 104.1% | 103.7% | |
| Working capital | $181.9M | $98.9M | $81.7M | $109.2M | $25.2M | |
| Invested capital | $182.8M | $100.1M | $83.3M | $109.4M | $25.4M | |
| Return on assets | -22.1% | -43.2% | -32.5% | -23.7% | -88.2% | |
| Operating ROA | -32.4% | -51.4% | -31.9% | -37.0% | -75.9% | |
| Return on tangible assets | -22.1% | -43.2% | -32.5% | -23.7% | -88.2% | |
| Return on equity | -23.3% | -48.1% | -35.2% | -27.1% | -198.8% | |
| Return on invested capital | -26.8% | -51.1% | -40.4% | -25.6% | -102.4% | |
| Return on capital employed | -26.9% | -51.3% | -40.6% | -27.3% | -126.1% | |
| Earnings yield | -2.4% | -11.5% | -21.9% | -23.4% | -190.0% | |
| Free cash flow yield | -2.3% | -9.2% | -24.0% | -22.7% | -162.0% | |
| Capex / Op. cash flow | -0.0% | -0.1% | -0.4% | -0.6% | 0.0% | |
| Capex / Depreciation | 8.3% | 23.8% | 111.4% | 369.8% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+336.4%EV / Sales n/aEV / EBITDA ▼-425.5%EV / Op. cash flow ▼-32.715Earnings yield ▲+0.092
Profitability
Return on equity ▲+0.247Return on assets ▲+0.211Return on invested capital ▲+0.244Return on capital employed ▲+0.245Operating ROA ▲+0.190Income quality ▲+0.186Tax burden ▼-0.001
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+9.246Net debt / EBITDA ▼-0.266Working capital ▲+82988000.000Invested capital ▲+82614000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+10068.2%EV / Sales n/aEV / EBITDA ▼-31901.5%EV / Op. cash flow ▼-42.882Earnings yield ▲+1.876
Profitability
Return on equity ▲+1.754Return on assets ▲+0.661Return on invested capital ▲+0.756Return on capital employed ▲+0.993Operating ROA ▲+0.435Income quality ▲+0.131Tax burden ▼-0.001
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+16.676Net debt / EBITDA ▼-0.253Working capital ▲+156674000.000Invested capital ▲+157345000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-15 Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-03 Trevi Therapeutics to Participate in Upcoming September Conferences NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September.
- 2026-08-26 Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough
- 2026-08-20 Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform Trevi Therapeutics leverages Haduvio''s dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio''s positive Phase II data in both IPF and RCC, ongoing pivotal trials, and robust liquidity underpin TRVI''s transition to a specialty pharma platform. TRVI''s specialty-first strategy targets concentrated pulmonology networks, enabling efficient market entry and future expansion without large-scale commercial buildout.
- 2026-08-07 Trevi Therapeutics Q2 Earnings Call Highlights Trevi Therapeutics NASDAQ: TRVI said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications.
- 2026-08-06 Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
- 2026-08-06 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026
- 2026-07-30 Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 6, 2026, at 4:30 p.m.
- 2026-07-28 Trevi Therapeutics to Participate in Upcoming August Conferences NEW HAVEN, Conn. , July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in August.
- 2026-07-28 Trevi Therapeutics to Participate in Upcoming August Conferences NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in August.